Literature DB >> 15067173

Analysis of Cox-2 and thromboxane synthase expression in pituitary adenomas and carcinomas.

Onder Onguru1, Bernd W Scheithauer, Kalman Kovacs, Sergio Vidal, Long Jin, Shuya Zhang, Katharina H Ruebel, Ricardo V Lloyd.   

Abstract

Recent studies have examined the role of cyclooxygenase-2 (Cox-2) expression in normal pituitaries and pituitary adenomas and have suggested a role for Cox-2 in the regulation of angiogenesis in the pituitary. Thromboxane synthase (TBXAS), which catalyzes the synthesis of thromboxane A2, is one of the downstream enzymes in Cox metabolism and appears to play a role in the regulation of invasiveness and angiogenesis in some neoplasms. To analyze the role of Cox-2 and TBXAS in pituitary tumor progression, we examined normal pituitaries (n = 8), pituitary adenomas (n = 174), and pituitary carcinomas (n = 7) for expression of Cox-2 and TBXAS by immunohistochemistry. Weak Cox-2 and moderate TBXAS expression was present in normal pituitary cells. Most pituitary adenomas showed increased expression of both Cox-2 and TBXAS. Pituitary tumors as a whole, but particularly carcinomas, showed greater Cox-2 expression than did normal pituitaries. Pituitary adenomas and carcinomas also showed greater staining for TBXAS when compared to normal pituitary. Nonfunctional adenomas had significantly higher levels of TBXAS expression compared to functional adenomas (p = 0.017). Adenomas and carcinomas showed similar degrees of staining for TBXAS. In summary, TBXAS appears to be one of the up-regulated downstream enzymes of Cox metabolism in pituitary tumors. Both Cox-2 and TBXAS may play an important role in pituitary tumor development and progression.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067173     DOI: 10.1385/ep:15:1:17

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   4.056


  48 in total

1.  Cellular localization of thromboxane synthase in ovine spinal cord and hindbrain.

Authors:  David Husted; Jenica Upshaw; Kelly E Gridley; Charles E Wood
Journal:  Brain Res       Date:  2003-05-02       Impact factor: 3.252

Review 2.  The role of COX-2 in breast and cervical cancer.

Authors:  Andrew J Dannenberg; Louise R Howe
Journal:  Prog Exp Tumor Res       Date:  2003

Review 3.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

4.  Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor.

Authors:  C Petersen; S Petersen; L Milas; F F Lang; P J Tofilon
Journal:  Clin Cancer Res       Date:  2000-06       Impact factor: 12.531

5.  Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis.

Authors:  T O Daniel; H Liu; J D Morrow; B C Crews; L J Marnett
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

6.  Gene transfer of thromboxane A(2) synthase and prostaglandin I(2) synthase antithetically altered tumor angiogenesis and tumor growth.

Authors:  Prasenohadi Pradono; Ryushi Tazawa; Makoto Maemondo; Masashi Tanaka; Kazuhiro Usui; Yasuo Saijo; Koichi Hagiwara; Toshihiro Nukiwa
Journal:  Cancer Res       Date:  2002-01-01       Impact factor: 12.701

7.  Genetic induction and upregulation of cyclooxygenase (COX) and aromatase (CYP19): an extension of the dietary fat hypothesis of breast cancer.

Authors:  R E Harris; F M Robertson; H M Abou-Issa; W B Farrar; R Brueggemeier
Journal:  Med Hypotheses       Date:  1999-04       Impact factor: 1.538

8.  Nitric oxide, prostanoids, cyclooxygenase, and angiogenesis in colon and breast cancer.

Authors:  R J Bing; M Miyataka; K A Rich; N Hanson; X Wang; H D Slosser; S R Shi
Journal:  Clin Cancer Res       Date:  2001-11       Impact factor: 12.531

9.  Chromogranin a processing in human pituitary adenomas and carcinomas: analysis with region-specific antibodies.

Authors:  Long Jin; Shuya Zhang; Jill Bayliss; Bernd Scheithauer; Xiang Qian; Ikuo Kobayashi; Mats Stridsberg; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 10.  Overview of physiological and pathophysiological effects of thromboxane A2.

Authors:  M L Ogletree
Journal:  Fed Proc       Date:  1987-01
View more
  7 in total

Review 1.  Cyclooxygenase-2 and thromboxane synthase in non-endocrine and endocrine tumors: a review.

Authors:  Onder Onguru; Mary B Casey; Sabine Kajita; Nobuki Nakamura; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2005       Impact factor: 3.943

Review 2.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

3.  Expression of laminin beta2: a novel marker of hypoxia in pituitary adenomas.

Authors:  Yijun Bao; Daizo Yoshida; Daijiro Morimoto; Akira Teramoto
Journal:  Endocr Pathol       Date:  2006       Impact factor: 3.943

Review 4.  Update information on drug metabolism systems--2009, part II: summary of information on the effects of diseases and environmental factors on human cytochrome P450 (CYP) enzymes and transporters.

Authors:  S Rendic; F P Guengerich
Journal:  Curr Drug Metab       Date:  2010-01       Impact factor: 3.731

5.  Expression of cyclooxygenase-2 (COX-2) in pituitary tumours.

Authors:  Grzegorz Sokołowski; Agata Bałdys-Waligórska; Małgorzata Trofimiuk; Dariusz Adamek; Alicja Hubalewska-Dydejczyk; Filip Gołkowski
Journal:  Med Sci Monit       Date:  2012-04

Review 6.  Genetic aspects of pituitary carcinoma: A systematic review.

Authors:  Zijiang Yang; Ting Zhang; Heng Gao
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

7.  Cyclooxygenase enzyme and PGE2 expression in patients with functional and non-functional pituitary adenomas.

Authors:  Nasrin Akbari; Mohammad Ghorbani; Vahid Salimi; Alimohammad Alimohammadi; Mohammad E Khamseh; Hamideh Akbari; Mitra Nourbakhsh; Alireza Sheikhi; S Fahimeh Taghavi; Masoumeh Tavakoli-Yaraki
Journal:  BMC Endocr Disord       Date:  2020-03-14       Impact factor: 2.763

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.